LB Pharmaceuticals Appoints New Executives
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
LB Pharmaceuticals announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. Prior to joining LB Pharmaceuticals, Ms. Rose served as Senior Vice President, Communications and Investor Relations at Lyell Immunopharma. Most recently Ms. Beaupre was the Chief Administrative Officer at Lyndra Therapeutics.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on LBRX
Wall Street analysts forecast LBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LBRX is 48.00 USD with a low forecast of 31.00 USD and a high forecast of 78.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.240
Low
31.00
Averages
48.00
High
78.00
Current: 21.240
Low
31.00
Averages
48.00
High
78.00
No data
About LBRX
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aktis Oncology Files for IPO in the U.S. Targeting $346 Million in Funding
- IPO Filing: Aktis Oncology filed for its initial public offering in the U.S. on Friday, signaling a rebound in biotech listings after a slowdown, as interest rates decline and capital inflows increase.
- Funding Background: Since its inception, Aktis Oncology has raised approximately $346 million, including a $175 million Series B funding round in 2024, reflecting institutional investors' confidence in its potential to develop treatments for various solid tumors.
- Financial Performance: For the nine months ended September 30, Aktis Oncology reported a net loss of $48.6 million, up from $31.9 million a year earlier, while revenue surged from $0.6 million to $4.6 million, indicating rising market demand.
- R&D Progress: The company's lead candidate, AKY-1189, is in early-stage studies, with preliminary data expected in the first quarter of 2027, focusing on treating multiple solid tumors, including advanced bladder cancer, breast cancer, and colorectal cancer.
Continue Reading
LB Pharmaceuticals Appoints New CCO and Grants 195,000 Stock Options
- Executive Appointment: On December 10, 2025, LB Pharmaceuticals appointed Kaya Pai Panandiker as the new Chief Commercial Officer and granted her 195,000 stock options under Nasdaq rules, reflecting the company's commitment to enhancing its executive team to drive business growth.
- Option Details: The options have an exercise price of $21.36 per share, a ten-year term, and vest over four years with 25% vesting on the first anniversary, which will incentivize the new executive to play a crucial role in the company's long-term development.
- Product Development Progress: LB-102, an oral small molecule ready for Phase 3 trials, has demonstrated significant efficacy and safety in Phase 2 trials, expected to provide new treatment options for schizophrenia and bipolar depression, further solidifying the company's market position.
- Market Potential: The successful approval of LB-102 could establish it as a mainstay in psychiatric treatment in the U.S., offering a more attractive alternative to existing branded and generic therapies, thereby driving LB Pharmaceuticals' long-term growth in the neuropsychiatric disease sector.
Continue Reading